 Home > Encyclopedia > Lumazine

Lumazine

Lumazine structure

CAS No:
487-21-8
Formula:
C6H4N4O2
Chemical Name:
Lumazine
Synonyms:
2,4(1H,3H)-Pteridinedione;Lumazine;2,4(3H,8H)-Pteridinedione;2,4-Pteridinediol;2,4-Dihydroxypteridine;Pteridine-2,4-dione;Lumazin;NSC 225113;NSC 41801;1,2,3,4-Tetrahydropteridine-2,4-dione;2,3,4,8-Tetrahydropteridine-2,4-dione;1H-Pteridine-2,4-dione;525-77-9;27899-40-7;27899-42-9
Categories:
Pharmaceutical Intermediates > Bulk Drug Intermediates

Request for Quotation

Description

LIGHT YELLOW TO OCHRE POWDER

Lumazine is a 2,4-dihydroxypteridine.

Lumazine Basic Attributes

Molecular Weight：

164.124

Exact Mass：

164.12

EC Number：

207-652-7

UNII：

260MF9U4WC

NSC Number：

225113|41801

DSSTox ID：

DTXSID0060068

HScode：

2933990090

Characteristics

PSA：

XLogP3：

-1.26

Density：

1.8±0.1 g/cm3

Melting Point：

348.5 °C

Boiling Point：

551.1±60.0 °C at 760 mmHg

Flash Point：

287.1±32.9 °C

Refractive Index：

1.809

Water Solubility：

H2O: 0.125 g/100 mL (25 ºC)

Collision Cross Section：

128.55 Å² [M-H]- [CCS Type: DT, Method: stepped-field]|132.4 Å² [M+H]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|143.8 Å² [M+Na]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|125.3 Å² [M-H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|126.6 Å² [M-H]-

Safety Information

wgk germany：

safety instructions：

S22-S24/25

RTECS Number：

UO3416000

Precautionary statement(s)：

P264, P270, P280, P301+P312, P305+P351+P338, P330, P337+P313, P501

Hazard Statements：

H302

Drug Information

MeSH Entry Terms：

2,4-pteridinedione

Lumazine Use and Manufacturing

Uses

Lumazine is a new MALDI matrix for complex (phospho)lipid mixtures analysis.

Manufacturing Info：

2,4(1H,3H)-Pteridinedione: INACTIVE

Computed Properties

Molecular Weight:164.12
XLogP3:-1
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:4
Exact Mass:164.03342538
Monoisotopic Mass:164.03342538
Topological Polar Surface Area:84
Heavy Atom Count:12
Complexity:230
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Drug Function and Efficacy

It has a direct relaxant effect on the smooth muscles of the respiratory tract; partly by inhibiting phosphodiesterase, thereby increasing the intracellular cAMP content; partly as a result of the release of endogenous adrenaline and norepinephrine; it can counteract the contractile effect of adenine and other substances on the respiratory tract; it enhances the contractility of the diaphragm and improves respiratory function.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Aminophylline sustained-release tablets
Ingredients	The content of anhydrous theophylline (C7H8N4O2) in this product should be 74.0% to 84.0% of the labeled amount of aminophylline, and the content of ethylenediamine (C2H8N2) should not be less than 11.25% of the labeled amount of aminophylline.
Indication	1. Diltiazem and verapamil can interfere with the metabolism of theophylline in the liver. When used in combination with this product, the blood concentration and toxicity of this product will be increased. 2. Cimetidine can reduce the liver clearance rate of this product. When used in combination, it can increase the serum concentration and (or) toxicity of theophylline. 3. Certain antibacterial drugs, such as erythromycin, roxithromycin, clarithromycin of macrolides, enoxacin, ciprofloxacin, ofloxacin, levofloxacin, clindamycin, lincomycin of fluoroquinolones, etc., can reduce the clearance rate of theophylline and increase its blood concentration, especially erythromycin and enoxacin. When theophylline is used in combination with the above drugs, the dosage should be appropriately reduced. 4. Phenobarbital, phenytoin, and rifampicin can induce liver enzymes and accelerate the liver clearance rate of theophylline; theophylline also interferes with the absorption of phenytoin. The plasma concentrations of both are reduced. The dosage should be adjusted when used in combination. 5. When used in combination with lithium salts, the renal excretion of lithium can be increased. Affect the effect of lithium salts. 6. When used in combination with mexiletine, the clearance of theophylline can be reduced, the concentration of theophylline in plasma can be increased, and the dosage needs to be adjusted. 7. When used in combination with caffeine or other xanthine drugs, their effects and toxicity can be increased.
Specifications	0.1g
Manufacturer	Changchun Norman Bethune Pharmaceutical Co., Ltd.

Aminophylline sustained-release tablets
Ingredients	The content of anhydrous theophylline (C7H8N4O2) in this product should be 74.0% to 84.0% of the labeled amount of aminophylline, and the content of ethylenediamine (C2H8N2) should not be less than 11.25% of the labeled amount of aminophylline.
Indication	1. Diltiazem and verapamil can interfere with the metabolism of theophylline in the liver. When used in combination with this product, the blood concentration and toxicity of this product will be increased. 2. Cimetidine can reduce the liver clearance rate of this product. When used in combination, it can increase the serum concentration and (or) toxicity of theophylline. 3. Certain antibacterial drugs, such as erythromycin, roxithromycin, clarithromycin of macrolides, enoxacin, ciprofloxacin, ofloxacin, levofloxacin, clindamycin, lincomycin of fluoroquinolones, etc., can reduce the clearance rate of theophylline and increase its blood concentration, especially erythromycin and enoxacin. When theophylline is used in combination with the above drugs, the dosage should be appropriately reduced. 4. Phenobarbital, phenytoin, and rifampicin can induce liver enzymes and accelerate the liver clearance rate of theophylline; theophylline also interferes with the absorption of phenytoin. The plasma concentrations of both are reduced. The dosage should be adjusted when used in combination. 5. When used in combination with lithium salts, the renal excretion of lithium can be increased. Affect the effect of lithium salts. 6. When used in combination with mexiletine, the clearance of theophylline can be reduced, the concentration of theophylline in plasma can be increased, and the dosage needs to be adjusted. 7. When used in combination with caffeine or other xanthine drugs, their effects and toxicity can be increased.
Specifications	0.1g
Manufacturer	Yabao Pharmaceutical Group Co., Ltd.

Aminophylline sustained-release tablets
Ingredients	The content of anhydrous theophylline (C7H8N4O2) in this product should be 74.0% to 84.0% of the labeled amount of aminophylline, and the content of ethylenediamine (C2H8N2) should not be less than 11.25% of the labeled amount of aminophylline.
Indication	1. Diltiazem and verapamil can interfere with the metabolism of theophylline in the liver. When used in combination with this product, the blood concentration and toxicity of this product will be increased. 2. Cimetidine can reduce the liver clearance rate of this product. When used in combination, it can increase the serum concentration and (or) toxicity of theophylline. 3. Certain antibacterial drugs, such as erythromycin, roxithromycin, clarithromycin of macrolides, enoxacin, ciprofloxacin, ofloxacin, levofloxacin, clindamycin, lincomycin of fluoroquinolones, etc., can reduce the clearance rate of theophylline and increase its blood concentration, especially erythromycin and enoxacin. When theophylline is used in combination with the above drugs, the dosage should be appropriately reduced. 4. Phenobarbital, phenytoin, and rifampicin can induce liver enzymes and accelerate the liver clearance rate of theophylline; theophylline also interferes with the absorption of phenytoin. The plasma concentrations of both are reduced. The dosage should be adjusted when used in combination. 5. When used in combination with lithium salts, the renal excretion of lithium can be increased. Affect the effect of lithium salts. 6. When used in combination with mexiletine, the clearance of theophylline can be reduced, the concentration of theophylline in plasma can be increased, and the dosage needs to be adjusted. 7. When used in combination with caffeine or other xanthine drugs, their effects and toxicity can be increased.
Specifications	0.1g
Manufacturer	Yantai Luyin Pharmaceutical Co., Ltd.

See More Related Drugs

Recommended Suppliers of Lumazine

Fulecare Contact Supplier

CN
1 YR

Business licensed

Trader Supplier of Slu-pp-332,BAM 15

High Quality 98% Lumazine Powder Antioxidant Protection Metabolic Regulation CAS 487-21-8

Unit Price: $25-30 /KG FOB

CAS No.: 487-21-8

Grade: cosmetic

Content: 99%

Inquiry
Cuicheng Biomedical Technology Contact Supplier

CN
1 YR

Business licensed Certified factory

Manufactory Supplier of Ginsenoside Rb1,Ginsenoside Rg1,Ginsenoside Re,Ginsenoside CK,Ginsenoside Rg2,Ginsenoside Rg5,Ginsenoside Rg5,Ginsenoside Rh2,Protopanaxatriol,Epmedin C,Icariin,Icaritin,Baohuoside I,Total Ginsenosides,Total Ginsenosides from Ginseng Stems And Leaves,Oridonin,Oleuropein,Curcumin,(20)-Ginsenoside Rg3,(20)-Protopanaxadiol

Pteridine-2,4(1H,3H)-dione

Unit Price: $29560-30000 /KG FOB

CAS No.: 487-21-8

Grade: Industrial Grade

Content: 98%

Inquiry